Derek K Ng1, Megan K Carroll2, Frederick J Kaskel3, Susan L Furth4,5, Bradley A Warady6, Larry A Greenbaum7. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street Room E7642, Baltimore, MD, 21205, USA. dng@jhu.edu. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street Room E7642, Baltimore, MD, 21205, USA. 3. Department of Pediatrics, Division of Nephrology, Albert Einstein College of Medicine, New York, NY, USA. 4. Department of Pediatrics, Division of Nephrology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 5. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA. 6. Department of Pediatrics, Division of Nephrology, Children's Mercy Kansas City, Kansas City, MO, USA. 7. Division of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA.
Abstract
BACKGROUND: Recombinant growth hormone (rGH) is an efficacious therapy for growth failure in children with chronic kidney disease (CKD). We described rGH use and estimated its relationship with growth and kidney function in the Chronic Kidney Disease in Children (CKiD) cohort. METHODS: Participants included those with growth failure, prevalent rGH users, and rGH initiators who did not meet growth failure criteria. Among those with growth failure, height z scores and GFR were compared between rGH initiators and non-initiators across 42 months. Inverse probability weights accounted for differences in baseline variables in weighted linear regressions. RESULTS: Among 148 children with growth failure and no previous rGH therapy, 42 (28%) initiated rGH therapy. Of the initiators, average age was 8.9 years, height z score was 2.50 standard deviations (SDs) (0.6th percentile), and GFR was 44 ml/min/1.73m2. They were compared to 106 children with growth failure who never initiated therapy (8.8 years, -2.33 SDs, and 51 ml/min/1.73m2). At 30 and 42 months after rGH, height increased +0.26 (95%CI: -0.11, +0.62) and +0.35 (95%CI: -0.17, +0.87) SDs, respectively, relative to those who did not initiate rGH. rGH was not associated with GFR. CONCLUSIONS: Participants with growth failure receiving rGH experienced significant growth, although this was attenuated relative to RCTs, and were more likely to have higher household income and lower GFR. A substantial number of participants, predominantly boys, without diagnosed growth failure received rGH and had the highest achieved height relative to mid-parental height. Since rGH was not associated with accelerated GFR decline, increasing rGH use in this population is warranted.
BACKGROUND: Recombinant growth hormone (rGH) is an efficacious therapy for growth failure in children with chronic kidney disease (CKD). We described rGH use and estimated its relationship with growth and kidney function in the Chronic Kidney Disease in Children (CKiD) cohort. METHODS: Participants included those with growth failure, prevalent rGH users, and rGH initiators who did not meet growth failure criteria. Among those with growth failure, height z scores and GFR were compared between rGH initiators and non-initiators across 42 months. Inverse probability weights accounted for differences in baseline variables in weighted linear regressions. RESULTS: Among 148 children with growth failure and no previous rGH therapy, 42 (28%) initiated rGH therapy. Of the initiators, average age was 8.9 years, height z score was 2.50 standard deviations (SDs) (0.6th percentile), and GFR was 44 ml/min/1.73m2. They were compared to 106 children with growth failure who never initiated therapy (8.8 years, -2.33 SDs, and 51 ml/min/1.73m2). At 30 and 42 months after rGH, height increased +0.26 (95%CI: -0.11, +0.62) and +0.35 (95%CI: -0.17, +0.87) SDs, respectively, relative to those who did not initiate rGH. rGH was not associated with GFR. CONCLUSIONS: Participants with growth failure receiving rGH experienced significant growth, although this was attenuated relative to RCTs, and were more likely to have higher household income and lower GFR. A substantial number of participants, predominantly boys, without diagnosed growth failure received rGH and had the highest achieved height relative to mid-parental height. Since rGH was not associated with accelerated GFR decline, increasing rGH use in this population is warranted.
Authors: D R Powell; F Liu; B K Baker; R L Hintz; P D Lee; S K Durham; E D Brewer; J W Frane; S L Watkins; R J Hogg Journal: Kidney Int Date: 1997-06 Impact factor: 10.612
Authors: Niels Thomas Hertel; Christer Holmberg; Kai A R Rönnholm; Bendt Brock Jacobsen; Klaus Olgaard; Gunnar W Meeuwisse; Mariane Rix; Fritz Bangsgaard Pedersen Journal: J Pediatr Endocrinol Metab Date: 2002-05 Impact factor: 1.634
Authors: Susan L Furth; Wenke Hwang; Ching Yang; Alicia M Neu; Barbara A Fivush; Neil R Powe Journal: Pediatr Nephrol Date: 2002-06 Impact factor: 3.714
Authors: George J Schwartz; Michael F Schneider; Paula S Maier; Marva Moxey-Mims; Vikas R Dharnidharka; Bradley A Warady; Susan L Furth; Alvaro Muñoz Journal: Kidney Int Date: 2012-08 Impact factor: 10.612